In EMT-6 breast cancer model, combination therapy enhanced antitumor efficacy relative to either monotherapy, induced the generation of tumor-specific immune memory, and enhanced T-bet expression and proliferation of NK and CD8+ T-cells (65). The gene discussed is CD8A; the disease is breast cancer.